Assessment of therapy response to Regorafenib by 18F-DOPA-PET/CT in patients with recurrent high-grade gliomas: a case series

Giorgio, Eugenio Di; Cuocolo, Alberto; Mansi, Luigi; Sicignano, Marilena; Squame, Fiorenzo; Gaudieri, Valeria; Giordano, Pasqualina; Giugliano, Francesco; Mazzaferro, Maria Pia; Negro, Alberto; Villa, Alessandro; Spadafora, Marco

doi:10.1007/s40336-021-00416-1

Cited by 2 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another anticancer therapy option with considerable efficacy in glioblastoma patients at recurrence is the multikinase inhibitor regorafenib, which is characterized by pronounced antiangiogenic activity (122). On the other hand, similar to glioma patients treated with standard chemoradiation using alkylating agents, equivocal MRI findings were also reported in glioma patients undergoing regorafenib treatment at recurrence (123)(124)(125). It has been suggested that amino acid PET using 18 F-FET or 18 F-FDOPA may help identify both treatment-related changes such as pseudoresponse or pseudoprogression and response to regorafenib (123)(124)(125).…”

Section: Assessment Of Treatment Responsementioning

confidence: 99%

Amino Acid PET in Neurooncology

et al. 2023

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to describe (1) advantages and limitations of anatomic MRI for brain tumor diagnostics; (2) the added clinical value of amino acid PET in glioblastoma patients or in patients with brain metastases for differential diagnosis, delineation of tumor extent, diagnosis of treatment-related changes, and assessment of treatment response; and (3) the differences in the information obtained by anatomical MRI and amino acid PET. Financial Disclosure: Drs. Galldiks and Lohmann received honoraria for lectures from Blue Earth Diagnostics, and Dr. Galldiks received honoraria for advisory board participation from Telix Pharmaceuticals. The authors of this article have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, SAM, and other credit types, participants can access this activity through the SNMMI website (http://www.snmmilearningcenter.org) through May 2026.For decades, several amino acid PET tracers have been used to optimize diagnostics in patients with brain tumors. In clinical routine, the most important clinical indications for amino acid PET in brain tumor patients are differentiation of neoplasm from nonneoplastic etiologies, delineation of tumor extent for further diagnostic and treatment planning (i.e., diagnostic biopsy, resection, or radiotherapy), differentiation of treatment-related changes such as pseudoprogression or radiation necrosis after radiation or chemoradiation from tumor progression at follow-up, and assessment of response to anticancer therapy, including prediction of patient outcome. This continuing education article addresses the diagnostic value of amino acid PET for patients with either glioblastoma or metastatic brain cancer.

show abstract